Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
September 23, 2015 1:25 PM EDTBofA/Merrill Lynch maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX) and raised its price target to $54.00 (from $46.00). The change follows positive phase 2 top-line results from HTX-011.
For an analyst ratings summary and ratings history on Heron Therapeutics... More
Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
September 23, 2015 11:00 AM EDTBrean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00), following announced positive top-line results from HTX-011. Analyst Jonathan Aschoff projects HTX-011 to have a higher price, and drive significant value.
Aschoff commented, "Yesterday, Heron announced positive top-line results from its Phase 2 trial of HTX-011 for the treatment of post-operative pain after bunionectomy. This randomized, placebo-controlled, double-blind, Phase 2 trial evaluated the... More
Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive Data
September 23, 2015 6:46 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on Heron Therapeutics (NASDAQ: HRTX) to $58.00 (from $47.00) after the company reported positive data evaluating HTX-011 in the PII bunionectomy trial, which showed reductions in pain intensity v. pbo over 24 hrs (-69%), 48... More
Heron Therapeutics (HRTX) Announces Top-Line Results From Phase 2 Study of HTX-011 in Post-Operative Pain
September 22, 2015 4:06 PM EDTHeron Therapeutics (NASDAQ: HRTX) today announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Herons proprietary Biochronomer® drug delivery... More
